Immucell (ICCC) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Immucell (ICCC) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn | 14.70% |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn | -0.23% |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn | 36.74% |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn | 36.15% |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn | 49.33% |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | -350.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49.33% |
| Dec 31, 2025 | -32.07% |
| Sep 30, 2025 | 40.25% |
| Jun 30, 2025 | 36.15% |
| Mar 31, 2025 | 25.29% |
| Dec 31, 2024 | 115.24% |
| Sep 30, 2024 | -88.98% |
| Jun 30, 2024 | -134.25% |
| Mar 31, 2024 | 0.26% |
| Dec 31, 2023 | 58.86% |
| Sep 30, 2023 | -42.79% |
| Jun 30, 2023 | -21.68% |
| Mar 31, 2023 | -166.53% |
| Dec 31, 2022 | -54.19% |
| Sep 30, 2022 | -9.24% |
| Jun 30, 2022 | -15.17% |
| Mar 31, 2022 | 72.01% |
| Dec 31, 2021 | 27.91% |
| Sep 30, 2021 | 37.35% |
| Jun 30, 2021 | 29.60% |